

Quick reference guide

Dronedaronone for the treatment of non-permanent atrial fibrillation

Guidance

- 1 Dronedaronone is recommended as an option for the treatment of non-permanent atrial fibrillation **only** in people:
 - whose atrial fibrillation is not controlled by first-line therapy (usually including beta-blockers), that is, as a second-line treatment option, **and**
 - who have at least one of the following cardiovascular risk factors:
 - hypertension requiring drugs of at least two different classes
 - diabetes mellitus
 - previous transient ischaemic attack, stroke or systemic embolism
 - left atrial diameter of 50 mm or greater
 - left ventricular ejection fraction less than 40% (noting that the summary of product characteristics [SPC] does not recommend dronedaronone for people with left ventricular ejection fraction less than 35% because of limited experience of using it in this group) **or**
 - age 70 years or older, **and**
 - who do not have unstable New York Heart Association (NYHA) class III or IV heart failure.
- 2 People who do not meet the criteria in section 1 who are currently receiving dronedaronone should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

Implementation tools

NICE has developed tools to help organisations put this guidance into practice (listed below). These are available on our website (www.nice.org.uk/guidance/TA197).

- Costing template and report to estimate the national and local savings and costs associated with implementation.
- Audit support for monitoring local practice.

Further information

Ordering information

You can download the following documents from www.nice.org.uk/guidance/TA197

- A quick reference guide (this document) – the recommendations.
- ‘Understanding NICE guidance’ – a summary for patients and carers.
- The NICE guidance.
- Details of all the evidence that was looked at and other background information.

For printed copies of the quick reference guide or ‘Understanding NICE guidance’, phone NICE publications on 0845 003 7783 or email publications@nice.org.uk and quote:

- N2274 (quick reference guide)
- N2275 (‘Understanding NICE guidance’).

NICE technology appraisal guidance 197

The guidance was developed using the NICE single technology appraisal process. NICE technology appraisal guidance is about the use of new and existing medicines and treatments in the NHS in England and Wales.

Related NICE guidance

For information about NICE guidance that has been issued or is in development, see www.nice.org.uk

Published

- Atrial fibrillation: the management of atrial fibrillation. NICE clinical guideline 36 (2006). Available from: www.nice.org.uk/guidance/CG36
- Percutaneous radiofrequency ablation for atrial fibrillation. NICE interventional procedure guidance 168 (2006). Available from: www.nice.org.uk/guidance/IPG168

Updating the appraisal

This technology appraisal will be considered for review in March 2013. Information about the progress of a review will be available at www.nice.org.uk/guidance/TA197

This guidance represents the view of NICE, which was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

© National Institute for Health and Clinical Excellence, 2010. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.